by Katie Nightingale | Feb 2, 2023 | Research
In the last 30 years there has been very little change to osteosarcoma (OS) treatment. We are dedicated to changing this. Through the Myrovlytis Trust, we fund research into OS, with a focus on finding new treatments. We are pleased to announce we have awarded funding...
by Katie Nightingale | Nov 22, 2022 | Research
There is an urgent need to find new therapies in osteosarcoma (OS) that has spread or has not responded to standard treatment. Identifying new treatments can be a long and complex process. One method of speeding up the process is to use drugs that already approved to...
by Katie Nightingale | Nov 15, 2022 | Research
There is a great need to develop new treatments for osteosarcoma (OS). This is particularly true for OS that has spread or has not responded to current standard therapy. Researchers are actively working towards finding new drugs to treat OS. To enable the drug...
by Katie Nightingale | Oct 18, 2022 | Research
In September 2022, we attended the Immuno UK conference. Held over 2 days in London, UK, this conference brought together over 260 people from industry and academic research. We heard the latest updates in the field of “immune oncology”. This can be described as...
by Katie Nightingale | Sep 20, 2022 | Research
Primary bone cancer (PBC) is a group of cancers that includes osteosarcoma (OS). Other cancers in this group are Ewing’s sarcoma, chondrosarcoma and chordoma. There have been few advances in the treatment of PBC for the past 40 years. This means there is an urgent...